Myocardial Protective Effects of Nicorandil During Percutaneous Coronary Intervention in Patients With Unstable Angina

Kim, Ju Han; Jeong, Myung Ho; Yun, Kyung Ho; Kim, Kye Hun; Kang, Dong Koo; Hong, Seo Na; Lim, Sang Yup; Lee, Sang Hyun; Lee, Yun Sang; Hong, Young Joon; Park, Hyung Wook; Kim, Weon; Ahn, Young Keun; Cho, Jeong Gwang; Park, Jong Chun; Kang, Jung Chaee

doi:10.1253/circj.69.306

Cited by 28 publications

(47 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cardioprotective effects of nicorandil in ischemic heart disease were reported in plenty of experimental and clinical studies [10,11,12]. These results indicate that inhibition of apoptosis by opening of mitoK ATP channels is one of the most important mechanisms of cardioprotective effects of nicorandil.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Effects of Nicorandil in Neuroprotective Activation of PI3K/AKT Pathways in a Cellular Model of Alzheimer's Disease

et al. 2013

View full text Add to dashboard Cite

Nicorandil, an ATP-sensitive potassium (K_ATP) channel opener, is known to have protective effects on ischemic injury in heart and brain. One of the most important protective mechanisms is the anti-apoptotic effect on cardiomyocytes and neurons. This study explored the anti-apoptotic effect of nicorandil against neurotoxicity in SH-SY5Y cells overexpressing the Swedish mutant APP (APPsw) and the possible mechanisms involved. We used SH-SY5Y cells transiently transfected with APPsw as a cellular model of Alzheimer's disease. Cells were treated with nicorandil (0.1, 0.5, 1 mM) for 24 h with and without glibenclamide (10 μM), a K_ATP channel inhibitor. The cells were then collected for MTT, apoptosis assay, and Western blot. In addition, we also investigated the potential involvement of the PI3K/Akt pathway in nicorandil-mediated neuroprotection of APPsw cells. Our results showed that nicorandil dose-dependently increased cell viability and reduced the rate of apoptosis as measured by MTT assay and annexin V/PI staining. Western blot showed that nicorandil could upregulate Bcl-2 levels and downregulate Bax and caspase-3 expression. Further studies showed that nicorandil increased the levels of phospho-Akt and upregulated element-binding protein activity by PI3K activation. Applying a PI3K inhibitor, LY294002 blocked the protection. All these findings suggest that nicorandil might be a potential treatment option for Alzheimer's disease.

show abstract

Section: Discussionmentioning

confidence: 85%

“…The cardioprotective effects of nicorandil in myocardial ischemia have been reported in a number of experimental and clinical studies [10,11,12]. In addition, there has also been evidence supporting mitoK ATP channel openers to protect the brain against ischemic injury in animal models [1,2,13].…”

Section: Introductionmentioning

confidence: 99%

Effects of Nicorandil in Neuroprotective Activation of PI3K/AKT Pathways in a Cellular Model of Alzheimer's Disease

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Nicorandil is also reported to inhibit myocardial damage during PCI in patients with unstable AP 25 and acute myocardial infarction. 26 Furthermore, Ishii et al 27 demonstrated that intravenous injection of nicorandil just before PCI leads to beneficial outcomes and prevents cardiovascular events of long duration and death in patients with STsegment-elevation myocardial infarction.…”

Section: Discussionmentioning

confidence: 94%

Double-Blind, Multicenter, Active-Controlled, Randomized Clinical Trial to Assess the Safety and Efficacy of Orally Administered Nicorandil in Patients With Stable Angina Pectoris in China

Zhu

Yuan-dong

Guo

et al. 2007

Circ J

View full text Add to dashboard Cite

Background The efficacy and safety of nicorandil were evaluated in Chinese patients with stable angina pectoris (AP) in a double-blind, multicenter, active-controlled, randomized clinical trial. Methods and ResultsAfter a 2-week washout period, 232 patients with stable AP were randomized to receive either nicorandil (5 mg tid; 115 patients) or isosorbide mononitrate (ISMN: 20 mg bid; 117 patients) for 2 weeks. Exercise capacity, number of weekly anginal attacks, nitroglycerin (NTG) consumption, and safety were evaluated. Nicorandil and ISMN significantly prolonged the time to 1 mm ST-segment depression in an exercise tolerance test. Both drugs improved the total exercise time and the time to onset of chest pain. There was no significant difference between the 2 groups. Nicorandil significantly decreased the number of anginal attacks and NTG consumption. ISMN decreased the number of anginal attacks significantly; however, there was no significance in NTG consumption, and the ratio of anginal attack reduction was at least 50% was significantly higher with nicorandil. Nicorandil was well tolerated and there was no safety profile difference compared with ISMN. Thus, nicorandil may have equivalent or better antianginal effect than ISMN. Conclusions Nicorandil is beneficial as treatment for AP. (Circ J 2007; 71: 826 -833)

show abstract

“…In an animal study by Tamura et al (9) a novel nitric oxide donor, nicorandil, has shown decrease in albu- (11) . They observed a significant decrease in proteinuria in nicorandil group whereas they showed that isosorbide dinitrate did not reduce proteinuria significantly.…”

Section: Allmentioning

confidence: 98%

Effect Of Oral Isosorbide Mononitrate Therapy On Proteinuria In Patients With Nephrotic Syndrome

Bakan¹,

Çaklılı²,

Ecder³

et al. 2018

IKSST

View full text Add to dashboard Cite

Objective: Proteinuria is the most important causitive factor in the progression of renal failure Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs etkiliyken (p=0,01), yalnız ACE veya yalnız ARB kullanan hastalarda etkili değildi (p=0,15). IMN aynı zamanda diyabetik hastalar da etkiliyken (p=0,02), tam tersine diyabetik olmayanlarda etkili değildi (p=0,33). Kalsiyum kanal blokeri kullanan hastalarda IMN etkisizdi (p=0,96

show abstract

Myocardial Protective Effects of Nicorandil During Percutaneous Coronary Intervention in Patients With Unstable Angina

Cited by 28 publications

References 33 publications

Effects of Nicorandil in Neuroprotective Activation of PI3K/AKT Pathways in a Cellular Model of Alzheimer's Disease

Effects of Nicorandil in Neuroprotective Activation of PI3K/AKT Pathways in a Cellular Model of Alzheimer's Disease

Double-Blind, Multicenter, Active-Controlled, Randomized Clinical Trial to Assess the Safety and Efficacy of Orally Administered Nicorandil in Patients With Stable Angina Pectoris in China

Effect Of Oral Isosorbide Mononitrate Therapy On Proteinuria In Patients With Nephrotic Syndrome

Contact Info

Product

Resources

About